1. Home
  2. SHEN vs DRUG Comparison

SHEN vs DRUG Comparison

Compare SHEN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shenandoah Telecommunications Co

SHEN

Shenandoah Telecommunications Co

HOLD

Current Price

$11.22

Market Cap

895.1M

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$74.28

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHEN
DRUG
Founded
1902
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Pharmaceuticals and Biotechnology
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
895.1M
744.9M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
SHEN
DRUG
Price
$11.22
$74.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$26.00
$129.25
AVG Volume (30 Days)
461.8K
257.8K
Earning Date
05-01-2026
05-15-2026
Dividend Yield
0.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$357,854,000.00
N/A
Revenue This Year
$7.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.08
N/A
52 Week Low
$9.67
$25.77
52 Week High
$17.35
$123.75

Technical Indicators

Market Signals
Indicator
SHEN
DRUG
Relative Strength Index (RSI) 21.91 54.33
Support Level $10.85 $72.18
Resistance Level $11.24 $74.92
Average True Range (ATR) 0.65 5.41
MACD -0.18 1.04
Stochastic Oscillator 0.44 69.86

Price Performance

Historical Comparison
SHEN
DRUG

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: